The Impact of HBV Therapy on Fibrosis and Cirrhosis
Source: The Impact of HBV Therapy on Fibrosis and Cirrhosis

Slideset

The Impact of HBV Therapy on Fibrosis and Cirrhosis

In this downloadable slideset, Jordan J. Feld, MD, MPH, illustrates the key data on optimal management of fibrosis and cirrhosis in HBV.
Format: Microsoft PowerPoint (.ppt)
File size: 546 KB
Date posted: 12/22/2016
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017    
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • EASL 2017: Emerging Therapies for Genotype 3 HCV

    Nancy Reau MD, FAASLD, AGAF - 5/12/2017    
    Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017    3 comments / Last Comment: 5/6/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.